DIETHYLPROPION HYDROCHLORIDE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for DIETHYLPROPION HYDROCHLORIDE (DIETHYLPROPION HYDROCHLORIDE).
Sympathomimetic amine with anorectic activity; stimulates release of norepinephrine and dopamine from presynaptic nerve terminals in the hypothalamus, leading to appetite suppression.
| Metabolism | Extensively metabolized via N-dealkylation to active metabolites (ethylaminopropiophenone, aminopropiophenone); minor CYP450 involvement; renal excretion of metabolites. |
| Excretion | Approximately 70-80% of the dose is excreted renally as metabolites; less than 10% as unchanged drug. Biliary/fecal excretion accounts for the remainder. |
| Half-life | 4-6 hours (parent drug); clinical effects correlate with plasma levels, requiring multiple daily dosing. |
| Protein binding | Approximately 80% bound to plasma proteins (mainly albumin). |
| Volume of Distribution | 3-4 L/kg, indicating extensive tissue distribution. |
| Bioavailability | Oral: 30-50% due to first-pass metabolism; intravenous: 100%. |
| Onset of Action | Oral: 30 minutes to 1 hour; intravenous bolus: immediate within 1-2 minutes. |
| Duration of Action | 4-6 hours (oral); shorter for IV (2-3 hours). Tolerance develops with prolonged use. |
25 mg orally three times daily, 1 hour before meals; extended-release: 75 mg orally once daily in midmorning.
| Dosage form | TABLET |
| Renal impairment | No specific guidelines; use caution in severe renal impairment (CrCl <30 mL/min). |
| Liver impairment | Contraindicated in severe hepatic impairment (Child-Pugh class C). Use with caution in moderate impairment (Child-Pugh class B), consider dose reduction. |
| Pediatric use | Not recommended for patients <16 years of age due to lack of safety and efficacy data. |
| Geriatric use | Use with caution; initiate at low end of dosing range due to increased sensitivity, potential for adverse effects (e.g., CNS excitation, hypertension). |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for DIETHYLPROPION HYDROCHLORIDE (DIETHYLPROPION HYDROCHLORIDE).
| Breastfeeding | Diethylpropion is excreted into breast milk in small amounts; M/P ratio unknown. Due to potential adverse effects on the infant including irritability, poor feeding, and possible cardiovascular effects, the manufacturer recommends discontinuing breastfeeding or the drug, weighing importance of therapy to mother. |
| Teratogenic Risk | Diethylpropion hydrochloride is classified as FDA Pregnancy Category B. Animal studies have not demonstrated fetal risk, but no adequate human studies exist. First trimester: Limited data suggest no increased risk of major malformations; however, use only if clearly needed. Second and third trimesters: Potential for fetal tachycardia, jitteriness, and withdrawal symptoms if used near term. Use not recommended due to maternal cardiovascular risks. |
■ FDA Black Box Warning
May be habit-forming; potential for abuse and dependence. Not recommended for patients with a history of drug abuse.
| Serious Effects |
Advanced arteriosclerosis; cardiovascular disease; moderate-to-severe hypertension; hyperthyroidism; glaucoma; agitation; history of drug abuse; during or within 14 days of MAO inhibitor therapy; pregnancy; lactation; hypersensitivity to sympathomimetics.
| Precautions | Pulmonary hypertension; cardiac valvulopathy; seizures; CNS stimulation (insomnia, restlessness); tachyphylaxis (discontinue if tolerance develops). |
Loading safety data…
| Fetal Monitoring | Monitor maternal blood pressure and heart rate regularly due to sympathomimetic effects. Assess fetal growth and heart rate via ultrasound and non-stress testing if used chronically. Observe neonate for signs of withdrawal (e.g., jitteriness, hypertonia) if used near delivery. |
| Fertility Effects | No definitive human data on fertility effects. Animal studies have shown no impairment of fertility at clinically relevant doses. Possible indirect effects due to anorexiant-induced malnutrition or hormonal changes. |